Eli Lilly's retatrutide cut weight 20.8% over 80 weeks in Phase 3; BLA planned for Q1 2027

Eli Lilly said its Phase 3 trial of retatrutide ran 80 weeks and produced average weight loss of 20.8%, and that it plans to submit a biologics license application for the drug in Q1 2027.

Detected & updated continuously · Source: Nebula